Colistimethate (COLISTIMETHATE SODIUM)
Colistimethate (COLISTIMETHATE SODIUM) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Colistimethate; Generic name: COLISTIMETHATE SODIUM; Manufacturer: Xellia Pharmaceuticals USA LLC.
| Brand name | Colistimethate |
|---|---|
| Generic name | COLISTIMETHATE SODIUM |
| Manufacturer | Xellia Pharmaceuticals USA LLC |
| Used for | INDICATIONS AND USAGE Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected |
| Dosage | DOSAGE AND ADMINISTRATION Important: Colistimethate for Injection, USP is supplied in vials containing colistimethate sodium equivalent to 150 mg colistin base activity per vial. Reconstitution for Intravenous or Intramuscular Administration The 150 mg vial should be reconstituted with 2 mL Sterile Water for Injection, USP. The reconstituted solution provides colistimethate sodium at a concentration equivalent to 75 mg/mL colistin base activity. During reconstitution swirl gently to avoid frothi |
| Warnings | WARNINGS Maximum daily dose calculated from colistin base activity should not exceed 5 mg/kg/day with normal renal function. Transient neurological disturbances may occur. These include circumoral paresthesia or numbness, tingling or formication of the extremities, generalized pruritus, vertigo, dizziness, and slurring of speech. For these reasons, patients should be warned not to drive vehicles or use hazardous machinery while on therapy. Reduction of dosage may alleviate symptoms. Therapy need |
| Active ingredient(s) | COLISTIMETHATE SODIUM |
| Route | INTRAMUSCULAR |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13dc3525-1879-4bd8-a922-81bc1397d5af |